Anticholinergic
PreclinicalSmall molecule
Anticholinergic is one of 11 small molecule programs targeting Enuresis. It is currently in Preclinical.
1
Indications
4
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in Enuresis
#DrugCompanyPhaseTrials
1Indocin
CCosette Pharmaceuticals, Inc.
Approved
Pitressin
AAultman Health Foundation
Approved
Advil
KKenvue Brands
Approved
Strattera
MMap77
Phase 1
Tofranil
SanofiPreclinical
Depacon
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Propiverine
AstellasPreclinical
Anticholinergic
SSeoul National University Hospital
Preclinical
Desmopresin
RRabin Medical Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Overactive Bladder2 trials
Myelomeningocele1 trial
Outcomes of Proactive Management of Children With Myelomeningocele
Recruiting·—··NCT06301802·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anticholinergic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details